Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1826 1
1953 1
1980 2
1981 1
1982 1
1985 1
1988 2
1989 1
1990 1
1991 3
1992 4
1993 3
1994 6
1995 6
1996 5
1997 1
1998 2
1999 3
2000 6
2001 4
2002 6
2003 9
2004 15
2005 11
2006 15
2007 15
2008 18
2009 19
2010 21
2011 18
2012 22
2013 14
2014 28
2015 27
2016 13
2017 13
2018 24
2019 20
2020 23
2021 29
2022 19
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

421 results

Results by year

Filters applied: . Clear all
Page 1
Challenges in glioblastoma research: focus on the tumor microenvironment.
Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, Ducray F, Enz-Werle N, Figarella-Branger D, Fournier I, Frenel JS, Gabut M, Galli T, Gavard J, Huberfeld G, Hugnot JP, Idbaih A, Junier MP, Mathivet T, Menei P, Meyronet D, Mirjolet C, Morin F, Mosser J, Moyal EC, Rousseau V, Salzet M, Sanson M, Seano G, Tabouret E, Tchoghandjian A, Turchi L, Vallette FM, Vats S, Verreault M, Virolle T. Bikfalvi A, et al. Among authors: sanson m. Trends Cancer. 2023 Jan;9(1):9-27. doi: 10.1016/j.trecan.2022.09.005. Epub 2022 Nov 16. Trends Cancer. 2023. PMID: 36400694 Review.
Transcriptome analysis reveals tumor microenvironment changes in glioblastoma.
Hoogstrate Y, Draaisma K, Ghisai SA, van Hijfte L, Barin N, de Heer I, Coppieters W, van den Bosch TPP, Bolleboom A, Gao Z, Vincent AJPE, Karim L, Deckers M, Taphoorn MJB, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer REM, Watts C, Angelopoulos N, Gorlia T, Golfinopoulos V, Bours V, van den Bent MJ, Robe PA, French PJ. Hoogstrate Y, et al. Among authors: sanson m. Cancer Cell. 2023 Apr 10;41(4):678-692.e7. doi: 10.1016/j.ccell.2023.02.019. Epub 2023 Mar 9. Cancer Cell. 2023. PMID: 36898379 Free article.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Wen PY, et al. Among authors: sanson m. Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106. Neuro Oncol. 2020. PMID: 32328653 Free PMC article. Review.
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities.
Garofano L, Migliozzi S, Oh YT, D'Angelo F, Najac RD, Ko A, Frangaj B, Caruso FP, Yu K, Yuan J, Zhao W, Di Stefano AL, Bielle F, Jiang T, Sims P, Suvà ML, Tang F, Su XD, Ceccarelli M, Sanson M, Lasorella A, Iavarone A. Garofano L, et al. Among authors: sanson m. Nat Cancer. 2021 Feb;2(2):141-156. doi: 10.1038/s43018-020-00159-4. Epub 2021 Jan 11. Nat Cancer. 2021. PMID: 33681822 Free PMC article.
Integrated proteogenomic characterization of glioblastoma evolution.
Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, Kwon HJ, Ha S, Garofano L, Oh YT, D'Angelo F, Kim CI, Kim S, Lee JY, Kim J, Hong J, Jang EH, Mathon B, Di Stefano AL, Bielle F, Laurenge A, Nesvizhskii AI, Hur EM, Yin J, Shi B, Kim Y, Moon KS, Kwon JT, Lee SH, Lee SH, Gwak HS, Lasorella A, Yoo H, Sanson M, Sa JK, Park CK, Nam DH, Iavarone A, Park JB. Kim KH, et al. Among authors: sanson m. Cancer Cell. 2024 Mar 11;42(3):358-377.e8. doi: 10.1016/j.ccell.2023.12.015. Epub 2024 Jan 11. Cancer Cell. 2024. PMID: 38215747
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. van den Bent MJ, et al. Among authors: sanson m. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000245 Free PMC article. Clinical Trial.
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy.
Migliozzi S, Oh YT, Hasanain M, Garofano L, D'Angelo F, Najac RD, Picca A, Bielle F, Di Stefano AL, Lerond J, Sarkaria JN, Ceccarelli M, Sanson M, Lasorella A, Iavarone A. Migliozzi S, et al. Among authors: sanson m. Nat Cancer. 2023 Feb;4(2):181-202. doi: 10.1038/s43018-022-00510-x. Epub 2023 Feb 2. Nat Cancer. 2023. PMID: 36732634 Free PMC article.
Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL. Touat M, et al. Among authors: sanson m. Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15. Nature. 2020. PMID: 32322066 Free PMC article.
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Meric-Bernstam F, et al. Among authors: sanson m. Cancer Discov. 2022 Feb;12(2):402-415. doi: 10.1158/2159-8290.CD-21-0697. Epub 2021 Sep 22. Cancer Discov. 2022. PMID: 34551969 Free PMC article. Clinical Trial.
421 results